Abstract
Abstract
Purpose
The purpose of this study is to show how the Ocular Compartmental Absorption & Transit (OCAT™) model in GastroPlus® can be used to characterize ocular drug pharmacokinetic performance in rabbits for ointment formulations.
Methods
A newly OCAT™ model developed for fluorometholone, as well as a previously verified model for dexamethasone, were used to characterize the aqueous humor (AH) concentration following the administration of multiple ointment formulations to rabbit. The model uses the following parameters: application surface area (SA), a fitted application time, and the fitted Higuchi release constant to characterize the rate of passage of the active pharmaceutical ingredient from the ointment formulations into the tears in vivo.
Results
Parameter sensitivity analysis was performed to understand the impact of ointment formulation changes on ocular exposure. While application time was found to have a significant impact on the time of maximal concentration in AH, both the application SA and the Higuchi release constant significantly influenced both the maximum concentration and the ocular exposure.
Conclusions
This initial model for ointment ophthalmic formulations is a first step to better understand the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug pharmacokinetic performance in rabbits.
Funder
U.S. Food and Drug Administration
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference39 articles.
1. Electronic Code of Federal Regulations (eCFR) [Internet]. Electronic Code of Federal Regulations (eCFR). 2020. Available from: https://www.ecfr.gov/. Accessed 15 Mar 2020.
2. Choi SH, Lionberger RA. Clinical, pharmacokinetic, and in vitro studies to support bioequivalence of ophthalmic drug products. AAPS J. 2016;18(4):1032–8.
3. Harigaya Y, Jiang X, Zhang H, Chandaroy P, Stier EM, Pan Y. Bioequivalence study methods with pharmacokinetic endpoints for topical ophthalmic corticosteroid suspensions and effects of subject demographics. Pharm Res. 2018;36(1):13.
4. U.S. FDA. Draft guidance on tobramycin [internet]. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tobramycin%20ophthalmic%20ointment%200.3%20NDA%20050555%20PSG%20Page%20RC%20May%202019.pdf. Accessed 02 May 2020.
5. US. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Internet]. 2018. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed 04 Aug 2020.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献